Sabin Vaccine Institute Receives $20.5 Million from BARDA with Potential of up to $128 Million to Develop Ebola Sudan and Marburg Vaccines

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced a funding award of $20.5 million with options for an additional $107.5 million from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services.

Sabin Vaccine Institute Elects New Trustees Bringing Expertise to Support Program Growth

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) announces the appointment of three new members to its Board of Trustees. Joining the Board are Drs. Elizabeth Fox, Saad Omer and Jacqueline Shea, well-respected leaders whose range of skills and experience promise to advance Sabin’s aim to ensure all people, everywhere get the vaccines they need.

GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute

LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.

Sabin Vaccine Institute and The Aspen Institute Release Report Calling for Bold, New, and Coordinated Commitments to Making Universal Influenza Vaccines a Reality

WASHINGTON, D.C. – A new report released today by the Sabin-Aspen Vaccine Science & Policy Group, a joint initiative of the Sabin Vaccine Institute and the Aspen Institute, calls for an urgent, coordinated effort to amplify and focus resources on the long-sought, but overdue achievement of a universal influenza vaccine (UIV).

Pages